Publications by authors named "CALTABIANO S"

Article Synopsis
  • - Daprodustat is a drug being tested for treating anemia in patients with chronic kidney disease, and this study examined how liver impairment affects its metabolism and safety.
  • - Participants with mild and moderate liver issues showed increased levels of daprodustat and its metabolites compared to healthy controls, with a 1.5- to 2.0-fold increase in drug exposure.
  • - Despite the higher drug levels in those with liver impairment, there were no significant changes in erythropoietin (EPO) levels, and no serious side effects were reported during the study.
View Article and Find Full Text PDF
Article Synopsis
  • Daprodustat, an oral medication being tested for treating anemia in chronic kidney disease, has undergone a study assessing its absorption, distribution, and excretion after both oral and IV doses in healthy men.
  • The study found that about 95% of the radiolabeled substance was recovered by day 5, primarily through feces, indicating it is mostly eliminated via the liver and intestines rather than the kidneys.
  • Daprodustat showed moderate oral bioavailability (about 66%) and low tissue distribution, with no serious side effects reported, suggesting it is generally well tolerated.
View Article and Find Full Text PDF
Article Synopsis
  • - Daprodustat is a drug that helps stimulate red blood cell production (erythropoiesis) by mimicking the body's response to low oxygen levels, making it a potential treatment for anemia related to chronic kidney disease (CKD).
  • - A study involving 64 healthy Japanese males tested two different tablet strengths of daprodustat to check if they were bioequivalent and how food impacted its absorption in the body.
  • - Results showed that the 2-mg and 4-mg daprodustat tablets were bioequivalent, and eating a standard meal did not significantly affect how the drug was processed in the body, with the drug being well tolerated among participants.
View Article and Find Full Text PDF
Article Synopsis
  • Daprodustat, a medication aimed at treating anemia in chronic kidney disease (CKD) patients undergoing hemodialysis, was studied for its effectiveness when given three times a week compared to standard daily doses.
  • A total of 103 hemodialysis patients, with hemoglobin levels between 9.0 to 11.5 g/dL, were randomized to receive different doses of daprodustat or a placebo over 29 days.
  • The results showed that daprodustat increased hemoglobin levels in a dose-dependent manner, was well tolerated, and established important dosing guidelines for further long-term studies in CKD treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Current treatments for anemia in chronic kidney disease (CKD) include iron supplements, blood transfusions, and erythropoietin replacement but have limitations; daprodustat is a new oral medication in Phase 3 trials that may overcome some of these issues.
  • The study aimed to evaluate the pharmacokinetics (how the drug behaves in the body) of daprodustat in different groups: those with normal kidney function, CKD patients not on dialysis, and those on hemodialysis (HD) or peritoneal dialysis (PD).
  • Results showed similar pharmacokinetic properties for daprodustat across all patient groups, indicating consistent absorption and metabolism, even in those undergoing dialysis. *
View Article and Find Full Text PDF

Motion information can reach V5/MT through two parallel routes: one conveying information at early latencies through a direct subcortical route and the other reaching V5 later via recurrent projections through V1. Here, we tested the hypothesis that input via the faster direct pathway depends on motion characteristics. To this end, we presented motion stimuli to healthy human observers at different velocities (4.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate daprodustat's ability to cause drug-drug interactions with the CYP2C8 enzyme and OATP1B1 transporter using pioglitazone and rosuvastatin as test drugs.
  • Results showed that daprodustat did not significantly affect the plasma levels of pioglitazone and rosuvastatin, suggesting low interaction potential as a perpetrator.
  • However, when daprodustat was taken with trimethoprim, a weak CYP2C8 inhibitor, its plasma concentration increased by 48%, indicating a moderate increase in absorption with the presence of weak inhibitors.
View Article and Find Full Text PDF
Article Synopsis
  • - Daprodustat, in phase 3 trials for treating anemia linked to chronic kidney disease, was tested for effects on heart function with 55 healthy volunteers receiving varying doses (75 and 500 mg) alongside moxifloxacin and placebo.
  • - The study found no significant increase in heart repolarization (QT interval) for daprodustat, with small decreases recorded that are not clinically important; however, moxifloxacin showed a notable increase.
  • - Adverse events were reported by 73% of participants, mostly from the 500 mg daprodustat group, which had more gastrointestinal issues, though the 75 mg dose was generally well tolerated with no new safety concerns.
View Article and Find Full Text PDF

This study characterized the pharmacokinetics, safety, and tolerability of retosiban in healthy, nonpregnant Japanese women prior to the enrollment of Japanese women in preterm labor in phase 3 trials. This study had 2 cohorts. Cohort 1 was a double-blind, sponsor-open, randomized study in Japanese women.

View Article and Find Full Text PDF
Article Synopsis
  • The study assessed the pharmacokinetics, pharmacodynamics, and safety of GSK1278863, a new prolyl hydroxylase inhibitor, through a single oral dose administration in Japanese (19 participants) and Caucasian (14 participants) subjects.
  • Increased exposure (measured by AUCinf) to the drug was found in Japanese subjects, likely related to differences in body weight, though both groups showed dose-proportional increases.
  • Significant increases in erythropoietin and vascular endothelial growth factor were noted in the Japanese group with higher doses, and while some adverse effects occurred, GSK1278863 was generally well tolerated with no notable ethnic differences in pharmacokinetic or pharmacodynamic responses.
View Article and Find Full Text PDF

Purpose: Retosiban is a small molecule oxytocin receptor antagonist that is under evaluation in clinical studies for treatment of spontaneous preterm labor. A Thorough QT/QTc study was conducted to evaluate the effect of retosiban on cardiac repolarization according to International Conference on Harmonization E14 guidance. This was a randomized, placebo- and positive-controlled, single-dose, crossover study of healthy men and women.

View Article and Find Full Text PDF
Article Synopsis
  • - Anemia, often seen in chronic kidney disease, is typically treated with erythropoiesis-stimulating agents, but a new drug, GSK1278863, shows promise as it promotes red blood cell production through a different mechanism by increasing hypoxia-inducible factor 1α levels.
  • - A study tested the effects of taking GSK1278863 alone, with a high-fat meal, and with gemfibrozil, a strong inhibitor of the enzyme that metabolizes the drug, CYP2C8.
  • - Results showed that food doesn't significantly impact GSK1278863's effectiveness, but if taken with gemfibrozil, the drug's concentration in the body can dramatically increase, which
View Article and Find Full Text PDF

Ronacaleret is an orally-active calcium-sensing receptor (CaSR) antagonist that has the potential for therapeutic utility in the stimulation of PTH release, notably as a bone anabolic agent comparable to recombinant human PTH(1-34) (rhPTH(1-34)). A recent study has shown that, despite the ability to increase circulating PTH levels in postmenopausal women in a dose-dependent manner, minimal effects of ronacaleret on bone mineral density have been observed. Therefore, the purpose of this study was to characterize the PTH profile as well as calcium metabolism parameters as a marker of PTH biological activity following the administration of ronacaleret or rhPTH(1-34).

View Article and Find Full Text PDF

A series of pyrazolo[4,3-d]pyrimidine sulfonamides and pyrazolo[3,4-d]pyrimidine sulfonamides have been synthesized. These compounds increase transcription of a calcitonin-luciferase promoter and production of cellular calcitonin in a calcitonin-secretion/RIA assay with minimized phosphodiesterase type 4 inhibitory activity at 30 microM as compared to structurally related xanthine methylene ketones such as denbufyllene. These two series are notable examples of small molecules that act as CT-inducers, a method to potentially treat bone loss diseases.

View Article and Find Full Text PDF

Augmentation of selective serotonin reuptake inhibitors (SSRIs) therapy by the 5-HT(1A) receptor agent pindolol may reduce the delay between initiation of antidepressant treatment and clinical response. This hypothesis is based on the ability of pindolol to block 5-HT(1A) autoreceptors in the dorsal raphe nuclei (DRN) and to potentiate the increase in 5-HT transmission induced by SSRIs. However, placebo-controlled clinical studies of pindolol augmentation of antidepressant therapy have reported inconsistent results.

View Article and Find Full Text PDF

Preclinical studies in rodents suggest that augmentation of serotonin reuptake inhibitors (SSRIs) therapy by the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor agent pindolol might reduce the delay between initiation of treatment and antidepressant response. This hypothesis is based on the ability of pindolol to potentiate the increase in serotonin (5-HT) transmission induced by SSRIs, an effect achieved by blockade of the 5-HT(1A) autoreceptors in the dorsal raphe nuclei (DRN). However, placebo-controlled clinical studies of pindolol augmentation of antidepressant therapy have reported inconsistent results.

View Article and Find Full Text PDF

A series of xanthine sulfonamides is presented as a class of calcitonin (CT) inducers - a potentially new method for treating diseases associated with postmenopausal bone loss such as osteoporosis. We have found that certain di-n-butylxanthine sulfonamides 4 upregulate CT transcription in a CT-luciferase reporter gene assay (CT-luci) and increase the production and release of CT in a CT secretion/RIA assay (CTS). In addition, these compounds do not have potent PDE4 inhibitory activity as do the related xanthine methylene ketones such as denbufyllene (2).

View Article and Find Full Text PDF

The ability of full-length human recombinant osteopontin (OPN) to support the adhesion of various alphav integrin-expressing cell lines was determined in order to characterize its integrin selectivity. The identity of this protein was assessed by cDNA sequence and mass spectroscopic analysis, and confirmed as full-length OPN. Neither the human embryonic kidney 293 cell line, which expresses the alphavbeta1 integrin, nor the human colonic adenocarcinoma HT-29 cell line, which expresses the alphavbeta5 integrin, were able to adhere to OPN; both of these cell lines are deficient in the beta3 subunit.

View Article and Find Full Text PDF

Chronic administration of vasopressin [antidiuretic hormone (ADH)] antagonists has been shown to produce a paradoxical antidiuresis in both ADH-replete and ADH-deplete (diabetes insipidus) rats. The antidiuretic effect is progressive, reaching maximal levels in 4 to 5 days, and sustained, persisting for at least 24 hr after cessation of treatment. The antidiuretic profiles associated with these antagonists do not coincide with the profiles of potent ADH agonists, arginine vasopressin and 1-deamino-8-D-arginine vasopressin.

View Article and Find Full Text PDF

Physiological regulation of receptor-effector pathways is recognized as a significant factor determining target organ selectivity and sensitivity in several hormonal systems. Whether or not physiological regulation of the renal vasopressin (V2) receptor-effector pathway participates in the control of body fluid homeostasis is unknown. We evaluated four states likely to be associated with altered sensitivities of the renal V2 receptor-effector pathway as follows: dehydration (18-h hydropenia), volume expansion, exogenous arginine vasopressin (AVP) infusion (10 ng/kg + 0.

View Article and Find Full Text PDF

Linear vasopressin analogs lacking a cyclic hexapeptide ring have recently been reported to possess vasopressin antagonist activity. In conscious, chronically catheterized, euhydrated Sprague-Dawley rats, we have compared the effects of two noncyclic vasopressin analogs, peptide 1 ([1-admantaneacetic acid,2-(O-ethyl)-D-tyr,4-val,6-(2-aminobutyric acid),9-arg]arginine vasopressin) and peptide 2 ([1-propionic acid, 2-(O-ethyl)-D-tyr,4-val,6-(2-aminobutyric acid),9- arg]arginine vasopressin), with a cyclic arginine vasopressin antagonist (SK&F 105494; [1-des cysteine, cyclo(2-O-ethyl-D-tyrosine,6-L-(2-amino-6,6-cyclopentamethylene suberic acid], 4-valine,7-arginine,8-D-arginine, 9-des glycine]-vasopressin). All three analogs caused a dose-dependent increase in urine flow by increasing free-water clearance without significantly changing osmotic clearance or sodium excretion, indicating true functional vasopressin antagonism.

View Article and Find Full Text PDF

Human syncytiotrophoblasts are derived from villous cytotrophoblasts by cell fusion. Coincident with this morphologic transformation, trophoblasts acquire specific endocrine functions, including elaboration of chorionic gonadotropin (hCG). We wondered if syncytia formation was a prerequisite for biochemical differentiation or simply was one part of the differentiation program.

View Article and Find Full Text PDF

Interpretation of studies designed to investigate the inhibitory action of vasopressin on gastric acid secretion has proven difficult, as the in vivo models are potentially susceptible to both direct (e.g. mucosal effects) and indirect effects (e.

View Article and Find Full Text PDF

Cytotrophoblasts, purified from human term placentae, were cultured in the absence or presence of 8-bromo-cAMP or 8-bromo-cGMP. 8-Bromo-cAMP provoked a dose-dependent increase in the secretion of hCG and progesterone within 24 h. After 48 h, hCG secretion increased by more than 200-fold, and progesterone secretion increased nearly 5-fold.

View Article and Find Full Text PDF